Diagnóstico y tratamiento farmacológico de la insuficiencia cardiaca crónica. Una revisión necesaria.
Resumen
La realización de múltiples ensayos clínicos y estudios multicéntricos en Cardiología, ha permitido reunir un enorme número de evidencias clínicas, que han modificado de forma radical el diagnóstico y tratamiento del síndrome de insuficiencia cardiaca. En la actualidad, las diferentes sociedades de Cardiología de Norteamérica y Europa han elaborado guías de buenas prácticas y guías de actuación que abordan el tema y establecen recomendaciones según sus grados y nivel de evidencia, para tratamientos complejos que tienen como objetivo tratar tanto la enfermedad como sus frecuentes complicaciones, prevenir su progresión, y adecuarse a cada período evolutivo de la misma. En esta publicación se hace una apretada síntesis de las mejores prácticas mundiales y se particulariza en la disponibilidad de medicamentos de nuestro cuadro básico. A forma de conclusión se establece, además, un grupo de recomendaciones prácticas para el médico generalista.
Descargas
Biografía del autor/a
Benerando Sevilla Pérez
Volfredo José Camacho Assef
Eva de la Nuez Ramos
Citas
Wood P. Heart failure. En: Wood P, editor. Diseases of the heart and circulation. London: Eyre and Spottiswoode; 1950. Braunwald E. Heart failure: an overview. En: Fishma AP, editor. Heart Failure. New York: McGraw-Hill; 1977.
Denolin H, Kuhn H, Krayenbuehl HP. The definition of heart failure. Eur Heart J. 1983; 4:445-8.
Poole-Wilson PA. Chronic heart failure causes pathophysiology, prognosis, clinical manifestations, investigation. En: Julian DG, Camm AJ, Fox KM, editors. Diseases of the Heart. London: Bailliere-Tindall; 1989. p. 48.
Cleland JG, Swedberg K, Follath F. The Euro Heart Failure Survey Programme¬, a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24:442-63.
Marantz PR, Budner N, Lense L. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 1988; 77:607-12.
Adams KF, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J. 1998; 135:S204-S15.
Giverts M, Colucci W, Braunwald E. Clinical aspects of heart failure; pulmonary edema, high-output failure, En: Zipes D, Libby P, Bonow R, Braunwald E, editors. Braunwald's heart disease. A textbook of cardiovascular medicine. 7th ed. Philadelphia: Elsevier Saunders; 2005. p. 539-68.
Vasan RS, Levy D. Defining diastolic heart failure: a call for standarized diagnostic criteria. Circulation. 2000; 101:2118-21.
Anguita Sánchez M, Ojeda PinedaS. Tratamiento médico de la insuficiencia cardiaca por disfunción diastólica. Rev Esp Cardiol. 2006; 6(Supl F):53-8.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the diagnosis and management of chronic heart failure in the adult. Circulation. 2005; 112:e154-235.
Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am CollCardiol. 2001; 38:2101-13.
Bosch X, Alfonso F, Bermejo J. Avances en la evaluación diagnóstica y terapéutica de la insuficiencia cardíaca. Del tratamiento tónico-deplectivo al trasplante celular y la regeneración miocárdica. Rev Esp Cardiol. 2004; 57:161-2.
Task Force on Acute Heart Failure. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005; 26:384-416.
Cleland JG, Ghosh J, Freemantle N. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO Lipids and cardiac resynchronization therapy in heart failure. Eur J Heart Fail. 2004; 6:501-8.
Fuster V, Ryde’n LE, Asinger RW. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001; 104:2118-50.
The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987; 316: 1429-1435.
SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 293-302.
Swedberg K, Held P, Kjekhus J, Rasmussen K, Rydén L, Wedel H, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992; 327: 678-684.
Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58.050 patients with suspected acute myocardial infarction. Lancet. 1995; 345: 669-685.
Guppo Italiano per lo Studio della Sopravivenza nell' infarcto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryltrinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343: 1115-1122.
Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13.634 patients with suspected acute myocardial infarction: intensive report from The Chinese Cardiac Study (CCS-1). Lancet. 1995; 345: 686-687.
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334: 1349-1355.
CIBIS-II Investigators and Committees. The Cardiac Insuficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet. 1999; 353: 9-13.
Hjalmarson A, Goldstein S, Fagenberg B, Wedel H, Waagstein F, Kjekshus J, et al; MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalisations, and well-being in patients with heart failure: the metoprolol cr/xl randomized intervention trial in congestive heart failure (MERIT-HF). JAMA. 2000; 283: 1295-1302.
RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting-enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]) Am J Cardiol. 1996; 78: 902-907.
Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, et al; PROVED Investigators Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am CollCardiol. 1993; 22: 955-962.
Packer M, Gheorghia de M, Young JB, Constantini PJ, Adams KF, Cody RJ, et al; Radiance Study. Withdraval of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993; 329: 1-7.
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525-533.
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbidedinitrate in the treatment of chronic heart failure. N Engl J Med. 1991; 325: 303-310.
The Multicenter Diltiazem Postinfarction Trial Research Group. The Effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988; 319: 385-392.
The Danish Study Group on verapamil in myocardial infarction. Secondary presentation with verapamil after myocardial infarction. Am J Cardiol. 1990; 66: 331-401.
Israeli Sprint Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomised intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988; 9: 354-364.
Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on mortality and morbidity in severe chronic heart failure. N Engl J Med. 1996; 335: 1107-1114.
Cohn J, Zische SM, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril V-HEFT III. Circulation. 1997; 96: 856-863.
The Cardiac Arrhythmia Suppression Trial. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989; 321:406-12.
Julian DG, Camm AJ, Fangin G, Janse M, Muñoz A, Schwartz PJ, et al. Randomized trial on effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. Lancet. 1997; 349: 667-674.
Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The department of veterans affairs CHF-STAT investigators. Circulation. 1998; 98: 2574-2579.
Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardialinfarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992; 327:669-77.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13.
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999; 353:2001-7.
Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357:1385-90.
Flather MD, Shibata MC, Coats AJ. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26:215-25.
Yusuff S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ.V, et al, for the CHARM Investigators and Committees. Lancet. 2003; 362:777-81.
González Juanatey JR, Mazón P, Varela A. Insuficiencia cardiaca con función sistólica conservada (insuficiencia cardiaca diastólica). En: Anguita M, editor. Manual de insuficiencia cardiaca. Madrid: Sociedad Española de Cardiología; 2003. p. 91-110.
Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part II. Causal mechanisms and treatment. Circulation. 2002; 105:1503-8.
Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001; 22:1527-60.
Setaro JF, Zaret BL, Schulman DS. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990; 66:981-6.
Bonow RO, Dilsizian V, Rosing DR. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long term effects. Circulation. 1985; 72:853-64.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Gamial TG, et al. ACC/AHA 2005 guidelines for the diagnosis and management of chronic heart failure in the adult [Internet] 2006 [citado 23 Mar 2012] [aprox. 8 pantallas]. Disponible en: www.acc.org/clinical/guidelines/failure/ind.pdf
Descargas
Cómo citar
Número
Sección
Licencia
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes de la Licencia CC Attribution-NonCommercial 4.0 International Deed (CC BY-NC 4.0):
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia.
Bajo las condiciones siguientes:
- Atribución — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
La revista no se responsabiliza con las opiniones y conceptos emitidos en los trabajos, son de exclusiva responsabilidad de los autores. El Editor, con la asistencia del Comité de Editorial, se reserva el derecho de sugerir o solicitar modificaciones aconsejables o necesarias. Son aceptados para publicar trabajos científico originales, resultados de investigaciones de interés que no hayan sido publicados ni enviados a otra revista para ese mismo fin.
La mención de marcas comerciales de equipos, instrumentos o materiales específicos obedece a propósitos de identificación, no existiendo ningún compromiso promocional con relación a los mismos, ni por los autores ni por el editor.
